J&J says MajesTEC-3 analysis projects near-general-population mortality risk for Tecvayli-Darzalex combo in early relapsed myeloma
JNJ•MajesTEC-3 model-based analyses
Johnson & Johnson released new model-based analyses from the Phase 3 MajesTEC-3 trial in relapsed or refractory multiple myeloma.
Results will be presented in two oral sessions at the International Myeloma Society Annual Meeting.
Modeling suggests the Tecvayli-Darzalex Faspro regimen could deliver durable disease control, reshaping long-term survival expectations at first relapse.
A separate analysis attributed the survival advantage mainly to fewer relapses versus standard regimens, without a meaningful rise in other deaths.
The readout supports the company’s push to move its BCMA bispecific therapy into earlier lines, reinforcing a potential new standard of care.
